Teresa Stanek Rea to step down from USPTO's top job

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Teresa Stanek Rea to step down from USPTO's top job

Teresa Stanek Rea, who has headed the USPTO since David Kappos left the Office in January, is to step down from her role as acting director

Teresa Rea

President Obama has not yet appointed a permanent successor to Kappos. Now that he has filled the position of Secretary of Commerce, however, he is expected to move quickly to appoint a new director – also known as the Under-Secretary of Commerce for Intellectual Property.

Rea is reported by Reuters to have emailed staff at the USPTO, telling them that she would resign “in the near future”.

She joined the Office in 2011 as deputy director after a career in private practice with Crowell & Moring. She has also worked as an in-house counsel after training as a pharmacist.

Rea told Managing IP at the Shanghai IP and Innovation Summit that she did not know when Obama is likely to announce his choice for Kappos’s successor, but that in the meantime the Office was “still on track and moving forward”.

more from across site and SHARED ros bottom lb

More from across our site

New platform, which covers SEPs covering the Wi-Fi 6 and Wi-Fi 7 standards, includes 10 patent owners
The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Gift this article